Technology ID
TAB-3921
Schweinfurthins and Uses Thereof
E-Numbers
E-183-2009-0
Lead Inventor
Reilly, Karlyne (NCI)
Co-Inventors
Wiemer, David (University of Iowa)
Beutler, John (NCI)
Turbyville, Thomas (Tommy) (NCI)
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Stages
Discovery
Lead IC
NCI
ICs
NCI
Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 per 3000 individuals on average. Patients develop a variety of developmental benign and malignant pathologies. The most common tumors associated with NF1 are peripheral sheath tumors, including neurofibromas, optical gliomas, and malignant peripheral nerve sheath tumors.
Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthin that inhibits growth of NF1-associated pathologies. The schweinfurthin analogs show inhibitory activity against mouse and human NF1 cancer cell lines. Glioma, diffuse B cell lymphoma, and leukemia cell lines also show significant sensitivity against the schweinfurthin analogs.
Competitive Advantages:
- Specificity of mode of action reduces potential side effects
- Novel mode of action
- Inhibitory activity against mouse and human NF1 cancer cell line
Commercial Applications:
- Therapies for tumors associated with NF1, for leukemia, and for diffuse B cell lymphoma
Licensing Contact: